Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
4.440
-0.010 (-0.22%)
Aug 13, 2025, 4:00 PM - Market closed
Monte Rosa Therapeutics Employees
Monte Rosa Therapeutics had 134 employees as of December 31, 2024. The number of employees increased by 1 or 0.75% compared to the previous year.
Employees
134
Change (1Y)
1
Growth (1Y)
0.75%
Revenue / Employee
$1,328,254
Profits / Employee
$180,358
Market Cap
274.21M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 134 | 1 | 0.75% |
| Dec 31, 2023 | 133 | 10 | 8.13% |
| Dec 31, 2022 | 123 | 30 | 32.26% |
| Dec 31, 2021 | 93 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GLUE News
- 7 days ago - Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 24 days ago - Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - GlobeNewsWire
- 5 weeks ago - Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 3 months ago - Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer - GlobeNewsWire
- 5 months ago - Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript - Seeking Alpha